Can you answer Q3
analyse_media
The answer is D) Mutations inactivating the vitamin D receptor.
Here is the reasoning:
Clinical breakdown:
- Alopecia + hypocalcemia since birth - this is the classic presentation of hereditary Vitamin D-resistant rickets (HVDRR), also called Vitamin D-dependent rickets type II
- Serum 1,25-(OH)2D3 is normal/elevated - the enzyme that makes active vitamin D (1-alpha-hydroxylase) is working fine, so the active hormone is present
- 24,25-(OH)2D is undetectable - 24-hydroxylase (encoded by CYP24A1) normally degrades 1,25-(OH)2D; if 24,25 is absent, this actually means the receptor is not working to induce 24-hydroxylase, so the hormone cannot signal its own degradation
- PTH is massively elevated (above assay limit) - secondary hyperparathyroidism due to persistent hypocalcemia
Why each other answer is wrong:
- A) Loss-of-function in calcium-sensing receptor - this causes familial hypocalciuric hypercalcemia (FHH), which produces hypercalcemia, not hypocalcemia
- B) Multiple endocrine neoplasia type I - MEN1 involves parathyroid, pituitary, and pancreatic tumors; it does not cause alopecia or this vitamin D pattern
- C) Mutations inactivating 24-hydroxylase - CYP24A1 loss-of-function would cause elevated 1,25-OH2D and hypercalcemia (not hypocalcemia), and would not cause alopecia
Key teaching point: When the vitamin D receptor (VDR) is non-functional, 1,25-(OH)2D cannot signal - so calcium cannot be absorbed, PTH shoots up, AND 24-hydroxylase (which is induced by VDR signaling) is never expressed, explaining why 24,25-(OH)2D is undetectable. Alopecia is a pathognomonic extra-skeletal feature of VDR mutations.
Answer: D
Q6 is melanoma
Yes, G) Malignant melanoma is correct.
Here is why:
Clinical features supporting melanoma:
- 63-year-old man - age is a risk factor
- Gradually enlarging lesion over 3 years on the forearm (sun-exposed site)
- The image shows a pigmented lesion with the classic ABCDE features of melanoma:
- Asymmetry - the lesion is not symmetric
- Border - irregular, notched border
- Color - variegated, with multiple shades of brown/dark pigment
- Diameter - appears close to or greater than 6 mm (scale bar shows 1 cm)
- Evolution - 3 years of gradual enlargement
Why the other options are wrong:
- A) Actinic keratosis - rough, scaly, flesh-colored; not a pigmented raised lesion
- B) Blue nevus - uniform blue-gray color, stable, typically not enlarging
- C) Compound nevus - benign mole, typically stable, uniform color
- D) Dermatofibroma - firm, flesh/brown button-like lesion, often on legs, does not enlarge progressively
- E) Halo nevus - central nevus with surrounding depigmented ring
- F) Hemangioma - red/purple vascular lesion
- H) Pyogenic granuloma - bright red, bleeds easily, rapid growth
- I) Seborrheic keratosis - "stuck-on" waxy appearance, uniform, well-defined
- J) Squamous cell carcinoma - typically hyperkeratotic, ulcerated, not deeply pigmented
The irregular border, color variation, and progressive enlargement over years in a sun-exposed area in an older male is the classic presentation of malignant melanoma.
Q7 and Q8
analyse_media
Q7 - Answer: B) Kidney
This is metastatic clear cell renal cell carcinoma (RCC) to the brain.
Clue-by-clue breakdown:
| Clue | Significance |
|---|---|
| Cells with clear/abundant cytoplasm on histology | Classic clear cell RCC - cells are packed with glycogen/lipid |
| Polycythemia | RCC secretes erythropoietin (paraneoplastic) |
| Hypercalcemia | RCC secretes PTHrP (paraneoplastic) |
| Microscopic hematuria | Primary kidney tumor bleeds into urine |
| EMA positive | Epithelial marker - supports carcinoma of renal tubular origin |
| CEA negative | Rules out colon, lung adenocarcinoma |
| 50 pack-year smoking history | Red herring - smoking is a risk factor for RCC too, but lung cancer would be CEA+/EMA variable |
The triad of polycythemia + hypercalcemia + hematuria is the paraneoplastic fingerprint of RCC. The clear cell histology confirms it.
Answer: B) Kidney
Q8 - Answer: A) The effect of confounding variables is decreased
This question is about the purpose of randomization in an RCT.
The key benefit of randomly assigning patients to treatment groups is that it distributes known and unknown confounders evenly between the two groups. This is the fundamental reason we randomize - it controls for variables we didn't measure or even think of.
Why the other options are wrong:
- B) Likelihood of achieving statistical significance is increased - Randomization does not affect statistical power; sample size does
- C) The power of the study is increased - Power depends on sample size, effect size, and alpha level - not randomization
- D) The study groups are equalized - This is a partial truth but describes the mechanism, not the benefit. Also, with only 48 vs. 52 patients, the groups are not perfectly equal in size - randomization doesn't guarantee equal group sizes
The correct answer captures the core purpose: randomization minimizes confounding, making the two groups comparable so any outcome difference can be attributed to the treatment.
Answer: A) The effect of confounding variables is decreased
This is a shared conversation. Sign in to Orris to start your own chat.